Bravecto^® 150 mg/ml powder and solvent for suspension for injection for dogs

There are no breed contraindications for this product. Any contraindications are listed in the product datasheet under summary of product characteristics.

There are no known incompatibilities with other classes of ectoparasiticides or parasiticide. It would be a reasonable precaution to observe a normal retreatment interval after the use of another product in the isoxazoline class and in the case of other products to not apply two products simultaneously so it was clear which product use was responsible in the unlikely occurrence of an adverse event.

MSD Animal Health conducts environmental risk assessments (ERAs) from development through product launch to understand and manage potential environmental impacts from manufacturing and patient use. These ERAs are conducted in accordance with applicable global regulations. Product environmental safety profiles are reassessed during periodic renewals, and risk mitigation actions are implemented when identified.

For our fluralaner-containing poultry product Exzolt, the European ERA evaluated the potential for transfer of active ingredient from excreta into surface waters. A Phase 2 environmental risk assessment (ERA) was required and therefore conducted for Exzolt because it is used in food-producing animals, whereas this level of assessment is not required for companion animal products like Bravecto. Since both products contain the same active ingredient, fluralaner, the additional environmental information generated for Exzolt enhances understanding of the environmental behaviour of fluralaner and is scientifically relevant when considering Bravecto. Based on the intrinsic properties of the active ingredient and the outcomes of these assessments, no transfer into surface water is expected under normal use conditions. Please note the statement in the Bravecto Spot-On Summary of Product Characteristics (SPC): dogs treated with Bravecto Spot-On should not be allowed to be immersed in water or swim in watercourses within 3 days after treatment.

Following administration in dogs, fluralaner is primarily excreted via the faeces. Exposure of bees to fluralaner from Bravecto-treated dogs is therefore considered very unlikely based on exposure pathways.

For Bravecto Injectable for dogs, the low dose of fluralaner delivers 12 months of flea and tick protection while resulting in a lower amount excreted over time compared with the higher-dose products of shorter duration. This prolonged protection with lower overall excretion supports Bravecto Injectable as a responsible choice for dogs when considering environmental stewardship and patient care.

As a general good-practice measure to minimise any potential environmental exposure from faecally excreted residues, all dog faeces should be promptly collected, bagged, and disposed of in accordance with local regulations.

The expiry date of the product is stated on the packaging and refers to the last day of that month. Do not use the product after the expiry date.